Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2022.2059053
Abstract: Abstract Background Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials. Methods These analyses included data for Investigator’s Global… read more here.
Keywords: atopic dermatitis; investigator global; quality life; global assessment ... See more keywords
Closing a gap: an investigator global assessment for use in hidradenitis suppurativa clinical trials
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Dermatology"
DOI: 10.1111/bjd.21713
Abstract: Well-designed clinical trials measuring valid outcomes that matter to patients 1 are pivotal in the response to the need for treatment in hidradenitis suppurativa (HS). Also known as acne inversa, this condition affects ≥ 1%… read more here.
Keywords: hidradenitis suppurativa; investigator global; global assessment; clinical trials ... See more keywords